Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy

European Journal of Ophthalmology
Sofija P DavidovićZoran Z Stošić

Abstract

Avastin (bevacizumab) intravitreal injections are widely used for treatment of diabetic retinopathy. The aim of our study was to analyze effect of 1.25 mg of intravitreal Avastin on serum concentration of vascular endothelial growth factor (VEGF) in diabetic patients. Participants were 10 diabetic patients on insulin therapy, without any other eye or systemic disease, and no kidney disfunction. Both eyes of diabetic patients were injected simultaneously with 1.25 mg of intravitreal Avastin, as a first step in treatment of nonproliferative diabetic retinopathy with clinically significant macular edema (4 patients), and of proliferative diabetic retinopathy (6 patients). Fluorescein angiography was performed prior to and laser therapy followed 1 month after Avastin treatment. VEGF concentration in patients serum was measured by ELISA technique: on the day of the Avastin administration, and 1, 7, and 28 days after intravitreal injection. In all analyzed participants, 24 hours after Avastin treatment, serum levels of VEGF were lower then basal (preinjection value). Maximal reduction of serum VEGF was noted on the 7th postoperative day. Twenty-eight days after, VEGF level in serum was raised, without completely reaching basal preope...Continue Reading

References

Feb 25, 2003·Progress in Retinal and Eye Research·A N WitmerR O Schlingemann
Nov 24, 2004·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert J Ignoffo
Jan 27, 2005·Investigative Ophthalmology & Visual Science·Jacques GaudreaultVanessa Shiu
May 1, 2007·Ophthalmology·Sophie J BakriRavinder J Singh
May 26, 2007·Investigative Ophthalmology & Visual Science·Peter HeiduschkaUNKNOWN Tübingen Bevacizumab Study Group
Dec 7, 2007·Investigative Ophthalmology & Visual Science·Hossein AmeriMark S Humayun
Jan 29, 2008·Current Diabetes Reviews·Rafael SimóCristina Hernández
Jul 19, 2008·American Journal of Ophthalmology·Tim U KrohneCarsten H Meyer
Mar 28, 2009·Investigative Ophthalmology & Visual Science·Hiroyuki NomotoTetsuya Baba
May 5, 2009·Ocular Immunology and Inflammation·Andrew J Barkmeier, Levent Akduman
Mar 10, 2010·Archives of Ophthalmology·Robert J CampbellSudeep S Gill
Nov 4, 2010·Acta Ophthalmologica·Michael WaisbourdAnat Loewenstein
Dec 9, 2010·Clinical Ophthalmology·Ronald E P FrenkelAngela Reyes
Dec 31, 2010·Japanese Journal of Ophthalmology·Masafumi OtaNagahisa Yoshimura

❮ Previous
Next ❯

Citations

Feb 8, 2014·Korean Journal of Ophthalmology : KJO·Donghyun WangSung Jin Lee
Oct 18, 2014·Seminars in Ophthalmology·Hasanain ShikariJennifer K Sun
Mar 8, 2014·British Journal of Clinical Pharmacology·Tsong Qiang Kwong, Moin Mohamed

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.